ABSTRACT
Imaging plays a critical role in the management of pheochromocytoma and paragangliomas (PPGL). Newly discovered molecular targets specifically targeting cell membranes or signaling pathways have brought nuclear medicine to the forefront in PPGL imaging. In addition to I-123/I-131 metaiodobenzylguanidine (MIBG) imaging, which has been used for many years, F-18 DOPA and specifically Ga-68 labeled somatostatin analogues (Ga-68 DOTA-sst) have shown excellent results in recent years as a potential alternative in the diagnosis and staging of PPGL. Concurrently, peptide receptor radionuclide therapy with Lu-177 labeled somatostatin analogues also looks like an alternative to I-131 MIBG therapy for the treatment of PPGL with improvement of clinical symptoms and/or disease control. In this review, we aimed to summarize the nuclear medicine imaging and treatment methods of patients with PPGL.
References
1Taïeb D, Hicks RJ, Hindié E, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019;46:2112-2137.
2Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99:1915-1942.
3Timmers HJ, Taieb D, Pacak K. Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma. Horm Metab Res 2012;44:367-372.
4de Wailly P, Oragano L, Radé F, et al. Malignant pheochromocytoma: new malignancy criteria. Langenbecks Arch Surg 2012;397:239-246.
5Timmers HJLM. Radionuclide Imaging of Pheochromocytoma and Paraganglioma in the Era of Multi-omics. Contemporary Endocrinology 2017.
6Oral A, Akgün A. I-123/I-131 Metaiodobenzylguanidine in Theranostics. Nuclear Medicine Seminars. Galenos Yayinevi 2015;1:92-102.
7Kara Gedik G, Aksoy T, Aydın F, et al. TSNM, Procedure Guideline for Radioiodinated MIBG Scintigraphy in Children 2.0. Nuclear Medicine Seminars. Galenos Yayinevi; 2015;1:50-56.
8Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endocrinol Metab 2010;95:2596-2606.
9van der Harst E, de Herder WW, Bruining HA, et al. [123 I]Metaiodobenzylguanidine and [ 111 In]Octreotide Uptake in Benign and Malignant Pheochromocytomas* [Internet]. Pathology (R.R.d.K.). 2001. Available from: https://academic.oup.com/jcem/article/86/2/685/2841043.
10Lumachi F, Tregnaghi A, Zucchetta P, et al. Sensitivity and positive predictive value of CT, MRI and 123 I-MIBG scintigraphy in localizing pheochromocytomas: A prospective study [Internet]. Nuclear Medicine Communications. 2006. Available from: http://journals.lww.com/nuclearmedicinecomm.
11Treglia G, Pascale M, Lazzeri E, van der Bruggen W, Delgado Bolton RC, Glaudemans AWJM. Diagnostic performance of 18F-FDG PET/CT in patients with spinal infection: a systematic review and a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2020;47:1287-1301.
12Han S, Suh CH, Woo S, Kim YJ, Lee JJ. Performance of 68Ga-DOTA-Conjugated Somatostatin Receptor-Targeting Peptide PET in Detection of Pheochromocytoma and Paraganglioma: A Systematic Review and Metaanalysis. J Nucl Med 2019;60:369-376.
13Taïeb D, Tessonnier L, Sebag F, et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas. Clin Endocrinol (Oxf) 2008;69:580-586.
14Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015;35:500-516.
15Carrasquillo JA, Chen CC, Jha A, Ling A, Lin FI, Pryma DA, Pacak K. Imaging of Pheochromocytoma and Paraganglioma. J Nucl Med 2021;62:1033-1042.
16Gonias S, Goldsby R, Matthay KK, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162-4168.
17Quach A, Ji L, Mishra V, et al. Thyroid and hepatic function after high-dose 131 I-metaiodobenzylguanidine (131 I-MIBG) therapy for neuroblastoma. Pediatr Blood Cancer 2011;56:191-201.
18Satapathy S, Mittal BR, Bhansali A. ‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta-analysis’. Clin Endocrinol (Oxf) 2019;91:718-727
19Demirci E, Kabasakal L, Toklu T, et al. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update. Nucl Med Commun 2018;39:789-796.
20Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol İmaging 2013;40:800-816.
